MARAGANORE JOHN — SEC insider filings
SEC reporting owner CIK 1180432. 34 insider filings on record with FilingPulse; latest filed 2026-10-22.
Transaction summary — filings shown
Covers all 34 filings on record, filed 2020-08-21 to 2026-10-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 9,411 shares, $248,891 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 35 legs across 6 filings — 205,445 shares, $31,116,710 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 69.
- Largest priced transaction: sale of 23,336 shares @ $199.92 ($4,665,333) in ALNYLAM PHARMACEUTICALS, INC., filed 2021-08-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Chief Executive Officer, Director | 10 | — | 35 legs · 205,445 sh · $31,116,710 | 32 |
| Rapport Therapeutics, Inc. (RAPP) | Director | 3 | 2 legs · 9,411 sh · $248,891 | — | 2 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | Director | 4 | — | — | 9 |
| Beam Therapeutics Inc. (BEAM) | Director | 6 | — | — | 6 |
| Hemab Therapeutics Holdings, Inc. (COAG) | Director | 1 | — | — | 5 |
| Kymera Therapeutics, Inc. (KYMR) | Director | 5 | — | — | 5 |
| CITY THERAPEUTICS, INC. (CTY) | Director | 2 | — | — | 4 |
| PROKIDNEY CORP. (PROK) | Director | 2 | — | — | 3 |
| TAKEDA PHARMACEUTICAL CO LTD (TAK) | Director | 1 | — | — | 3 |
Insider filings — MARAGANORE JOHN
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-22 | 4 | Rapport Therapeutics, Inc. (RAPP) | Purchase (P): 8,239 @ $26.38 · Purchase (P): 1,172 @ $26.92 | EDGAR |
| 2026-10-19 | 4 | CITY THERAPEUTICS, INC. (CTY) | Conversion (C): 610,759 · Grant/award (A): 22,649 (derivative) @ $0 · Conversion (C): 500,000 (derivative) @ $0 · Conversion (C): 56,095 (derivative) @ $0 | EDGAR |
| 2026-10-15 | 3 | CITY THERAPEUTICS, INC. (CTY) | Holdings only — no transactions reported | EDGAR |
| 2026-07-06 | 4 | TAKEDA PHARMACEUTICAL CO LTD (TAK) | Grant/award (A): 3,800 @ $0 · Disposition to issuer (D): 1,152 (derivative) @ $4,931.20 · Grant/award (A): 1,319 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Kymera Therapeutics, Inc. (KYMR) | Grant/award (A): 6,068 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Rapport Therapeutics, Inc. (RAPP) | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Beam Therapeutics Inc. (BEAM) | Grant/award (A): 19,676 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) | Conversion (C): 17,974 · Conversion (C): 17,974 · Grant/award (A): 107,338 (derivative) @ $0 · Conversion (C): 817 (derivative) @ $0 · Conversion (C): 817 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Kymera Therapeutics, Inc. (KYMR) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Rapport Therapeutics, Inc. (RAPP) | Grant/award (A): 21,850 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Beam Therapeutics Inc. (BEAM) | Grant/award (A): 33,662 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Kymera Therapeutics, Inc. (KYMR) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Beam Therapeutics Inc. (BEAM) | Grant/award (A): 23,114 (derivative) @ $0 | EDGAR |
| 2023-07-03 | 4 | PROKIDNEY CORP. (PROK) | Grant/award (A): 48,128 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | Kymera Therapeutics, Inc. (KYMR) | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Beam Therapeutics Inc. (BEAM) | Grant/award (A): 16,532 (derivative) @ $0 | EDGAR |
| 2022-09-02 | 4 | Beam Therapeutics Inc. (BEAM) | Grant/award (A): 10,391 (derivative) @ $0 | EDGAR |
| 2022-07-13 | 4 | PROKIDNEY CORP. (PROK) | Grant/award (A): 614,013 (derivative) @ $0 · Grant/award (A): 614,013 (derivative) @ $0 | EDGAR |
| 2022-06-23 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Grant/award (A): 4,975 (derivative) @ $0 · Grant/award (A): 29,307 (derivative) @ $0 | EDGAR |
| 2022-05-24 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 1,585 @ $0 · Option exercise (M): 1,585 (derivative) @ $0 | EDGAR |
| 2022-01-19 | 4 | Kymera Therapeutics, Inc. (KYMR) | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2021-12-23 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 14,167 @ $0 · Tax withholding (F): 6,315 @ $189.13 · Tax withholding (F): 2 @ $190.50 · Tax withholding (F): 319 @ $186.02 | EDGAR |
| 2021-12-14 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 1,036 @ $96.45 · Option exercise (M): 1,124 @ $88.95 · Option exercise (M): 839 @ $119.13 · Option exercise (M): 2,368 @ $42.22 · Option exercise (M): 2,368 (derivative) @ $0 · Option exercise (M): 1,124 (derivative) @ $0 · +2 more | EDGAR |
| 2021-11-12 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 33,978 @ $7.10 · Sale (S): 10,365 @ $170.36 · Sale (S): 7,742 @ $171.35 · Sale (S): 14,518 @ $172.22 · Sale (S): 683 @ $173.25 · Sale (S): 670 @ $174.34 · +1 more | EDGAR |
| 2021-11-08 | 4 | Beam Therapeutics Inc. (BEAM) | Grant/award (A): 13,133 (derivative) @ $0 | EDGAR |
| 2021-08-16 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 33,979 @ $7.10 · Sale (S): 2,441 @ $198.02 · Sale (S): 4,160 @ $198.93 · Sale (S): 23,336 @ $199.92 · Sale (S): 3,828 @ $200.84 · Sale (S): 214 @ $201.55 · +1 more | EDGAR |
| 2021-06-02 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Gift (G): 3,415 @ $0 · Option exercise (M): 1,686 @ $0 · Option exercise (M): 1,686 (derivative) @ $0 | EDGAR |
| 2021-05-24 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Grant/award (A): 1,585 (derivative) @ $0 · Grant/award (A): 8,888 (derivative) @ $0 | EDGAR |
| 2021-05-17 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 33,979 @ $7.10 · Sale (S): 3,015 @ $128.30 · Sale (S): 4,512 @ $129.32 · Sale (S): 9,121 @ $130.34 · Sale (S): 11,203 @ $131.18 · Sale (S): 3,481 @ $132.32 · +3 more | EDGAR |
| 2021-04-21 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 16,236 @ $0 · Tax withholding (F): 7,237 @ $131.75 · Tax withholding (F): 270 @ $134.62 | EDGAR |
| 2021-02-26 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 33,979 @ $7.10 · Sale (S): 1,001 @ $143.88 · Sale (S): 6,129 @ $145.15 · Sale (S): 9,376 @ $146.13 · Sale (S): 6,097 @ $146.98 · Sale (S): 4,375 @ $148 · +8 more | EDGAR |
| 2021-02-16 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 14,166 @ $0 · Tax withholding (F): 5,412 @ $156 · Tax withholding (F): 307 @ $151.94 · Grant/award (A): 17,504 (derivative) @ $0 | EDGAR |
| 2020-11-20 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 34,765 @ $9.14 · Sale (S): 18,987 @ $123.55 · Sale (S): 5,489 @ $124.49 · Sale (S): 10,187 @ $125.35 · Sale (S): 102 @ $126.62 · Option exercise (M): 34,765 (derivative) @ $0 | EDGAR |
| 2020-08-21 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 34,765 @ $9.14 · Sale (S): 4,775 @ $135.09 · Sale (S): 21,448 @ $136.07 · Sale (S): 8,542 @ $136.86 · Option exercise (M): 34,765 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1180432 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs